Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 1
2003 3
2004 5
2005 8
2006 6
2007 10
2008 8
2009 2
2010 7
2011 3
2012 10
2013 12
2014 14
2015 9
2016 10
2017 12
2018 5
2019 5
2020 11
2021 16
2022 19
2023 19
2024 24
2025 27
2026 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Results by year

Filters applied: . Clear all
Page 1
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma.
Tanaka K, Tsuji K, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Ishikawa T, Tajiri K, Ochi H, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Hatanaka T, Kakizaki S, Noritake H, Kawata K, Naganuma A, Kosaka H, Matsui K, Matono T, Kuroda H, Yata Y, Tanaka H, Aoki T, Tamai H, Tada F, Ohama H, Kanayama Y, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Yoshida O, Imai M, Nakamura S, Enomoto H, Kaibori M, Kudo M, Hiasa Y, Kumada T; Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Tanaka K, et al. Among authors: tanaka h. Liver Cancer. 2025 Jul 21. doi: 10.1159/000547519. Online ahead of print. Liver Cancer. 2025. PMID: 41063740 Free PMC article.
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis.
Hatanaka T, Yata Y, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Kakizaki S, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Naganuma A, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Komatsu S, Tamai H, Okamura J, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Matsuura T, Noritake H, Enomoto H, Kaibori M, Fukumoto T, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hatanaka T, et al. Among authors: tanaka h. Hepatol Res. 2026 Jan;56(1):89-99. doi: 10.1111/hepr.70033. Epub 2025 Sep 6. Hepatol Res. 2026. PMID: 40913797
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma.
Tomonari T, Shimose S, Saeki I, Tani J, Honma Y, Ito T, Takeuchi M, Naito T, Takeuchi Y, Sasaki R, Sasaki K, Hatanaka T, Kakizaki S, Kanayama Y, Naganuma A, Tanabe N, Tanaka H, Kawano Y, Sato Y, Nishina S, Miyaaki H, Otsuka M, Kawashima H, Harada M, Kobara H, Takami T, Kawaguchi T, Takayama T; Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group. Tomonari T, et al. Among authors: tanaka h. Hepatol Res. 2025 Aug;55(8):1184-1192. doi: 10.1111/hepr.14212. Epub 2025 May 28. Hepatol Res. 2025. PMID: 40433908
Impact of time-of-day atezolizumab plus bevacizumab combination therapy infusion for unresectable hepatocellular carcinoma: A retrospective multicenter study.
Naganuma A, Kakizaki S, Hatanaka T, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Yata Y, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Naganuma A, et al. Among authors: tanaka h. Hepatol Res. 2025 May;55(5):741-751. doi: 10.1111/hepr.14171. Epub 2025 Feb 9. Hepatol Res. 2025. PMID: 40317628
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Tanaka H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tamai H, Komatsu S, Tada F, Nakamura S, Nakamura Y, Miyake T, Yoshida O, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Matsuura T, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Matsui K, Kaibori M, Fukumoto T, Hiasa Y, Kudo M, Kumada T; RELPEC Group and HCC 48 Group. Ohama H, et al. Among authors: tanaka h. J Gastroenterol. 2025 Nov;60(11):1427-1436. doi: 10.1007/s00535-025-02290-4. Epub 2025 Aug 20. J Gastroenterol. 2025. PMID: 40833596
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study.
Hatanaka T, Yata Y, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Kakizaki S, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Koshiyama Y, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Matsui K, Naganuma A, Tanaka H, Ohama H, Kuroda H, Matono T, Aoki T, Ochi H, Imai M, Nakamura S, Kanayama Y, Tanaka K, Tada F, Yoshida O, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T; Real‐life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hatanaka T, et al. Among authors: tanaka h. Liver Int. 2025 Jul;45(7):e70192. doi: 10.1111/liv.70192. Liver Int. 2025. PMID: 40558097
221 results